Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.

IF 3 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-07-23 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S527579

Jovana Ristic, Sena Kodalak, Gonzalo Alberto Peralta-Jiménez, Maria Fernanda Moura de Lima, Marijana Kovacevic, Srdjan Masic, Tatjana Nikolic

{"title":"Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.","authors":"Jovana Ristic, Sena Kodalak, Gonzalo Alberto Peralta-Jiménez, Maria Fernanda Moura de Lima, Marijana Kovacevic, Srdjan Masic, Tatjana Nikolic","doi":"10.2147/DMSO.S527579","DOIUrl":null,"url":null,"abstract":"Purpose: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin's potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM).Methods: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher's Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model.Results: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69-2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher's Z = 0.4; 95% CI: 0.240-0.554, p < 0.001) and body mass index (BMI) (Fisher's Z = 0.17; 95% CI: 0.036-0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher's Z = -0.35; 95% CI: -0.471 to -0.239, p < 0.001).Conclusion: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"2493-2506"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301137/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S527579","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin's potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM).

Methods: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher's Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model.

Results: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69-2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher's Z = 0.4; 95% CI: 0.240-0.554, p < 0.001) and body mass index (BMI) (Fisher's Z = 0.17; 95% CI: 0.036-0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher's Z = -0.35; 95% CI: -0.471 to -0.239, p < 0.001).

Conclusion: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.

Abstract Image

查看原文本刊更多论文

成人2型糖尿病和糖尿病肾病患者的血凝素水平：系统回顾和荟萃分析

目的：糖尿病肾病（DKD）由于慢性肾脏疾病并发症而显著影响健康和医疗保健费用。鉴于asprosin作为疾病进展的生物标志物的潜力，我们对成人2型糖尿病（T2DM）患者中asprosin与DKD的关系进行了首次系统回顾和荟萃分析。方法：系统检索PubMed、Embase、Cochrane、Web of Science。采用95%置信区间（CI）的标准均值差异（SMD）和Fisher’s Z变换来检验asprosin与DKD之间的关系。偏倚风险采用纽卡斯尔-渥太华量表（NOS）及其横断面研究版本进行评估。异质性（I²> 50%）采用随机效应模型分析。结果：纳入6项研究（n = 1340）。荟萃分析结果显示，伴有微量/大量蛋白尿的T2DM患者的循环asprosin水平明显高于正常蛋白尿的T2DM患者（SMD: 1.5, 95% CI: 0.69-2.32, p = 0.0003）。相关性荟萃分析显示，asprosin与尿白蛋白排泄比（UACR）呈正相关(Fisher’s Z = 0.4；95% CI: 0.240-0.554, p < 0.001)和身体质量指数（BMI） (Fisher’s Z = 0.17；95% CI: 0.036-0.301, p = 0.013)，与估计肾小球滤过率（eGFR）呈负相关(Fisher’s Z = -0.35；95% CI: -0.471 ~ -0.239, p < 0.001)。结论：Asprosin在伴有早期DKD和DKD的T2DM患者中升高，并与疾病严重程度的关键标志物相关。需要进一步的研究来更好地了解asprosin的病理生理机制及其在DKD中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.